Takeda

Adcetris (brentuximab vedotin) as an add-on to first-line chemotherapy significantly extends the time to disease worsening or death in patients with peripheral T-cell lymphoma (PTCL) whose tumors are positive ... Read more

TAK-659, an investigational compound being developed by Takeda Pharmaceuticals, is able to target lymphomas associated with Epstein-Barr virus (EBV) infection, preventing their growth and spread, a mouse study shows. ... Read more

The U.S. Food and Drug Administration approved the combination of Seattle Genetics’ Adcetris (brentuximab vedotin) with chemotherapy for the treatment of adults with previously untreated stage 3 or 4 classical ... Read more

The European Commission has approved Adcetris (brentuximab vedotin) as a treatment for adults with cutaneous T-cell lymphoma (CTCL) whose cancer produces the CD30 molecule. It had previously given the ... Read more

Adcetris (brentuximab vedotin) in combination with chemotherapy is a valuable treatment option for patients with previously untreated advanced Hodgkin’s lymphoma, researchers said after revealing data from a Phase 3 ... Read more

The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin’s lymphoma, according to Seattle Genetics. The supplemental Biologics ... Read more

The U.S. Food and Drug Administration has granted Adcetris (brentuximab vedotin) Breakthrough Therapy Designation as a treatment with chemotherapy for patients with previously untreated advanced classical Hodgkin lymphoma. The designation, ... Read more

Britain’s national health service advisory agency has made a decision that will make Adcetris (brentuximab vedotin) more accessible as a treatment for an aggressive type of lymphoma. The National Institute for Health ... Read more

Bothell, Washington-based Seattle Genetics, Inc. — a biotechnology company focused on development and commercialization of innovative antibody-based therapies for the treatment of cancer — and Takeda Pharmaceutical Company Limited ... Read more

Lymphoma News Today

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more